Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Wednesday morning,Benzinga reports. BTIG Research currently has a $39.00 price objective on the stock.

A number of other equities research analysts have also recently commented on the stock. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 target price for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Wedbush raised their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Needham & Company LLC upped their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, Chardan Capital reiterated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Stoke Therapeutics Price Performance

STOK opened at $22.86 on Wednesday. The business’s 50-day moving average is $26.47 and its two-hundred day moving average is $17.17. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $38.69. The firm has a market capitalization of $1.31 billion, a PE ratio of 34.12 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. As a group, sell-side analysts expect that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the transaction, the director directly owned 91,585 shares in the company, valued at approximately $1,843,606.05. This trade represents a 33.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total value of $300,529.08. Following the completion of the transaction, the general counsel directly owned 18,176 shares in the company, valued at approximately $366,064.64. The trade was a 45.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 186,607 shares of company stock valued at $4,224,210 over the last quarter. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares in the last quarter. Strs Ohio acquired a new position in shares of Stoke Therapeutics during the third quarter worth about $150,000. Osaic Holdings Inc. raised its holdings in Stoke Therapeutics by 263.3% during the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after purchasing an additional 5,427 shares in the last quarter. Finally, State of Wyoming purchased a new position in Stoke Therapeutics during the third quarter worth about $184,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.